Business Information
The group’s principal activities include researching, discovering and developing drugs. The products of the group include Defibrotide, Urokinase, Calcium heparin and Sulglicotide. Specific customer of the group is Crinos Industria Farmacobiologica. The group operates from the United States and Korea. Of the total revenue in the year 2005, Defibrotide accounted for $2,476, Urokinase $684, Calcium heparin $125, Sulglicotide $53 and other $23 (thousands)
|
|
Name |
Title
|
Email
|
| Giorgio Iacobone | Chmn., Statutory Auditor | N/A | | Gary Gemignani | CFO, Exec. VP | N/A | | Massimo Iacobelli | Sr. VP, Scientific Dir. | N/A | | Salvatore Calabrese | VP - Finance, Sec. | N/A | | Alessandro Gianni | Member - Scientific Advisory Board | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 5,709 | (18,970) | | 2005 | 4,312 | (14,591) | | 2004 | 4,767 | (9,066)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
